← Gilead Sciences overview

Gilead Sciences vs Eli Lilly and: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Gilead Sciences Inc (GILD)

Q3 2026
▲2▼1

Gilead Q3: strong HIV sales and raised guidance offset by huge acquisition losses

  • Q2 beat and guidance raised twice Gilead's Q2 revenue beat at $7.8B, up 10%, and management raised full-year guidance twice to $30.1–30.4B. The dividend also rose 3.8%, signaling confidence in the business.

    This is the core new financial result and outlook that drove the stock this quarter.

  • HIV franchise strength and new approvals HIV sales rose 12% to $5.7B, with Yeztugo surging and Bixlenvo approved. A once-weekly oral HIV regimen advanced, and a legal win blocked illegal Biktarvy imports, protecting the franchise.

    HIV is Gilead's biggest business, and these new gains are central to the quarter's positive momentum.

  • Massive acquisition charges and cash drain Gilead took $11.2B in acquired IPR&D charges from Arcellx, Tubulis, and Ouro, causing large GAAP and non-GAAP losses and cutting cash from $10.6B to $3.2B. This is a real financial counterweight.

    These charges and the cash decline are the main negative force that weighed on the stock this quarter.

  • Pipeline progress but early-stage and pricing unclear Pipeline wins included Trodelvy's EU expansion and anito-cel, but these remain early-stage with no near-term revenue. Lenacapavir access pricing is still unclear, leaving uncertainty about future profits.

    This captures the mixed nature of pipeline advances that are promising but not yet contributing revenue.

August 2026
▲2▼1

Gilead's Q2 Beat, Raised Guidance, New Launches Offset Big Acquisition Costs

  • Q2 beat and raised guidance Gilead's second-quarter revenue beat expectations at $7.8 billion, up 10%, and management raised full-year guidance twice to $30.1–$30.4 billion. The dividend also rose 3.8%, signaling confidence in the business.

    This is the core financial result that drove positive sentiment during the period.

  • HIV franchise strength and new launches HIV sales climbed 12% to $5.7 billion, PrEP topped $1 billion quarterly, and Yeztugo jumped to $232 million from $15 million. Bixlenvo won FDA approval, Trodelvy expanded in the EU, and lenacapavir licensing widened.

    These are the key operational drivers showing growth beyond the core HIV business.

  • Large acquisition charges hit earnings and cash Gilead took $11.2 billion in acquired IPR&D charges from Arcellx, Tubulis, and Ouro Medicines, causing large GAAP and non-GAAP losses and cutting cash from $10.6 billion to $3.2 billion. This is a real cost of future growth, though not an operating cash drain.

    This is the main counterweight that pressured reported results and the balance sheet.

  • Pipeline wins are early-stage Positive pipeline news, such as the once-weekly oral HIV regimen and new drug launches, remains early and not yet contributing near-term revenue. Investors weigh future potential against current costs.

    This explains why pipeline progress is not yet a near-term earnings driver, balancing optimism.

Latest
▲3

Gilead lifts 2026 outlook and dividend as HIV sales surge

  • Raised 2026 sales outlook and dividend hike Gilead raised its 2026 product sales outlook to $30.1–$30.4 billion and lifted its quarterly dividend 3.8%. Stronger guidance tells investors the HIV business is performing better than expected, which supports the stock price.

    This is the period's biggest new event and directly answers what is driving GILD now.

  • HIV franchise sales accelerate Quarterly HIV sales rose 12% to $5.7 billion, led by Biktarvy at $3.8 billion and Descovy up 48%. Yeztugo, the twice-yearly prevention shot, jumped to $232 million from $15 million a year earlier, showing the new product is taking off.

    HIV is Gilead's core profit engine, and its growth is the fundamental force behind the raised guidance.

  • Big acquisition charges create reported losses Gilead recorded $11.2 billion in acquired research charges from buying Arcellx, Tubulis and Ouro Medicines, causing large accounting losses and cutting cash to $3.2 billion from $10.6 billion. This is a real cost of building future growth, but it does not reflect day-to-day operations.

    It is the main counterweight to the good news and explains why reported earnings look weak despite strong sales.

  • New lenacapavir licensing and FDA approval widen reach Gilead expanded royalty-free lenacapavir licensing to a once-yearly HIV prevention shot across 120 lower-income countries, and won FDA approval for Bixlenvo, a small once-daily HIV pill. Both broaden the HIV portfolio and add future sales.

    These regulatory and access moves extend Gilead's HIV leadership, a key long-term driver.

September 2026
▲4

Gilead's HIV franchise strengthens with legal win, access deal, and analyst backing

  • Fourth Circuit blocks illegal imports of Biktarvy A federal appeals court upheld an injunction stopping foreign versions of Gilead's top HIV drug Biktarvy from being sold in the U.S. This protects Gilead's U.S. sales and pricing power, supporting the stock.

    This legal win directly protects Gilead's largest revenue stream and removes a competitive threat.

  • PAHO deal expands lenacapavir access in Latin America Gilead and the Pan American Health Organization agreed to make HIV prevention drug lenacapavir available in 14 Latin American countries. This widens the market for Gilead's prevention portfolio, though pricing terms are still unclear.

    This expands Gilead's global reach for a key growth drug, but the financial impact depends on final pricing.

  • Morgan Stanley reaffirms Overweight on HIV prevention growth Morgan Stanley kept its buy rating on Gilead, highlighting the HIV prevention franchise. Yeztugo, a twice-yearly shot, is expected to hit $1 billion in first-year sales, with the prevention portfolio at about $4 billion annually and PrEP users more than doubling since 2022.

    Analyst backing and concrete sales targets reinforce confidence in Gilead's growth trajectory.

  • Gilead's pipeline advances with gamgertamig and anito-cel Lakefront Biotherapeutics plans registrational trials in 2027 for gamgertamig, which Gilead will commercialize. Also, Gilead's anito-cel for multiple myeloma has an FDA decision due in December. These add future growth options beyond HIV.

    Pipeline progress diversifies Gilead's revenue and offers new catalysts, though they are not yet near-term revenue.

▲4

Gilead's HIV franchise strengthens with legal win, access deal, and analyst backing

  • Fourth Circuit blocks illegal imports of Biktarvy A federal appeals court upheld an injunction stopping foreign versions of Gilead's top HIV drug Biktarvy from being sold in the U.S. This protects Gilead's U.S. sales and pricing power, supporting the stock.

    This legal win directly protects Gilead's largest revenue stream and removes a competitive threat.

  • PAHO deal expands lenacapavir access in Latin America Gilead and the Pan American Health Organization agreed to make HIV prevention drug lenacapavir available in 14 Latin American countries. This widens the market for Gilead's prevention portfolio, though pricing terms are still unclear.

    This expands Gilead's global reach for a key growth drug, but the financial impact depends on final pricing.

  • Morgan Stanley reaffirms Overweight on HIV prevention growth Morgan Stanley kept its buy rating on Gilead, highlighting the HIV prevention franchise. Yeztugo, a twice-yearly shot, is expected to hit $1 billion in first-year sales, with the prevention portfolio at about $4 billion annually and PrEP users more than doubling since 2022.

    Analyst backing and concrete sales targets reinforce confidence in Gilead's growth trajectory.

  • Gilead's pipeline advances with gamgertamig and anito-cel Lakefront Biotherapeutics plans registrational trials in 2027 for gamgertamig, which Gilead will commercialize. Also, Gilead's anito-cel for multiple myeloma has an FDA decision due in December. These add future growth options beyond HIV.

    Pipeline progress diversifies Gilead's revenue and offers new catalysts, though they are not yet near-term revenue.

▲4

Gilead's HIV engine accelerates with new drug approvals and raised guidance

  • HIV sales growth guidance raised to 9–10% Gilead lifted its full-year HIV sales growth outlook to 9–10% from 8%, citing a $4 billion annualized PrEP business and strong Biktarvy. Higher expected sales mean more profit, which supports a higher stock price.

    This is a direct, new upgrade to the company's core revenue outlook, a key driver of the stock.

  • FDA approves Bixlenvo, a new single-tablet HIV regimen The FDA approved Bixlenvo, a once-daily single tablet for complex HIV cases. It is the smallest such option and the first for patients who cannot take existing single-tablet therapies, opening a new market and reinforcing Gilead's HIV leadership.

    A new product approval expands the addressable market and future revenue, directly lifting growth prospects.

  • European Commission expands Trodelvy approval in first-line TNBC The EC approved Trodelvy plus Keytruda for first-line metastatic triple-negative breast cancer, making it the only antibody-drug conjugate plus immunotherapy combo in that setting across the EU. This widens oncology sales and diversifies revenue beyond HIV.

    A major regulatory win in a new indication that boosts the oncology franchise and long-term growth.

  • Pipeline expands with MacroGenics option and once-weekly HIV data Gilead exercised an option on a MacroGenics bispecific cancer program, and positive Phase 3 results for a once-weekly oral HIV regimen with Merck were announced. These add future growth options, though they are early and not yet near-term revenue.

    New pipeline additions signal longer-term growth potential, which can support a higher valuation.

▲3▼1

Gilead's Q2 beat and raised guidance show HIV strength, but acquisition charges hit reported EPS

  • Q2 revenue beat and raised full-year guidance Gilead reported Q2 revenue of $7.8 billion, up 10% and above estimates, and raised 2026 product sales guidance to $29.8–$30.1 billion. HIV sales rose 12% to $5.7 billion, with Biktarvy up 7%. This shows the core business is growing faster than expected, which supports a higher stock price.

    This is the period's central event and directly explains the positive fundamental momentum behind GILD.

  • PrEP franchise tops $1 billion; Yeztugo persistence strong Quarterly PrEP sales doubled year-over-year to over $1 billion for the first time, led by the twice-yearly shot Yeztugo ($232 million, up 40% from Q1). Over 70% of patients stayed on Yeztugo after a year, the best among PrEP options. This growing prevention business adds a new revenue stream and reduces reliance on HIV treatment alone.

    It highlights a key new growth driver that is boosting investor confidence and future sales.

  • Large acquisition charges push reported EPS deeply negative Gilead's Q2 GAAP EPS was a loss of $8.45, and non-GAAP EPS was a loss of $6.75, due to $11.2 billion in acquired IPR&D expenses from buying Arcellx, Tubulis, and Ouro Medicines. Excluding these one-time charges, EPS would be $8.50–$8.85. The headline loss may scare some investors, but it is an accounting effect, not a cash drain on operations.

    It is the main counterweight in the period and explains why reported earnings look bad despite strong operations.

  • Analyst reiterates Buy; pipeline advances in oncology and HIV BofA reiterated a Buy rating and $162 price target, citing Yeztugo's persistence and raised guidance. Separately, European regulators backed Trodelvy plus Keytruda for first-line triple-negative breast cancer, and a once-weekly oral HIV regimen with Merck met its Phase 3 goals. These expand future sales opportunities.

    It shows external validation and pipeline progress that support the stock's longer-term growth story.

July 2026
▲4

Gilead's pipeline expands with new launches and positive HIV data

  • Four drug launches planned to diversify beyond HIV Gilead is preparing four drug launches this year, including bulevirtide for hepatitis delta and anito-cel for multiple myeloma. This diversification reduces reliance on HIV and opens new revenue streams, supporting the stock.

    This is a new strategic update that shows Gilead's growth beyond its core HIV business.

  • Positive Phase 3 results for once-weekly oral HIV regimen Gilead and Merck reported that a once-weekly oral HIV treatment maintained viral suppression in Phase 3 trials, with higher patient satisfaction. This could become the first once-weekly oral option, strengthening Gilead's HIV portfolio.

    This is a new clinical milestone that could lead to a new product and boost future sales.

  • CHMP recommends Trodelvy plus Keytruda for first-line TNBC The European regulator recommended Trodelvy combined with Keytruda for first-line metastatic triple-negative breast cancer. This expands Trodelvy's use and reinforces its role, potentially increasing sales in Europe.

    This is a new regulatory step that could lead to approval and broader use of a key drug.

  • Remdesivir evaluated in Ebola trial The WHO began an experimental Ebola trial in Congo, testing Gilead's remdesivir. If effective, it could expand remdesivir's use and demand, though the impact is uncertain and likely small.

    This is a new potential use for an existing drug, but the financial impact is not yet clear.

▲4

Gilead's pipeline expands with new launches and positive HIV data

  • Four drug launches planned to diversify beyond HIV Gilead is preparing four drug launches this year, including bulevirtide for hepatitis delta and anito-cel for multiple myeloma. This diversification reduces reliance on HIV and opens new revenue streams, supporting the stock.

    This is a new strategic update that shows Gilead's growth beyond its core HIV business.

  • Positive Phase 3 results for once-weekly oral HIV regimen Gilead and Merck reported that a once-weekly oral HIV treatment maintained viral suppression in Phase 3 trials, with higher patient satisfaction. This could become the first once-weekly oral option, strengthening Gilead's HIV portfolio.

    This is a new clinical milestone that could lead to a new product and boost future sales.

  • CHMP recommends Trodelvy plus Keytruda for first-line TNBC The European regulator recommended Trodelvy combined with Keytruda for first-line metastatic triple-negative breast cancer. This expands Trodelvy's use and reinforces its role, potentially increasing sales in Europe.

    This is a new regulatory step that could lead to approval and broader use of a key drug.

  • Remdesivir evaluated in Ebola trial The WHO began an experimental Ebola trial in Congo, testing Gilead's remdesivir. If effective, it could expand remdesivir's use and demand, though the impact is uncertain and likely small.

    This is a new potential use for an existing drug, but the financial impact is not yet clear.

Q2 2026
▲3▼1

Gilead's Trodelvy and HIV pipeline win key approvals, but earnings guidance weighs

  • FDA and EU approve Trodelvy for first-line triple-negative breast cancer Gilead won U.S. and European approval to use Trodelvy as an initial treatment for metastatic triple-negative breast cancer, a hard-to-treat disease. This opens a much larger patient group and could significantly boost sales, pushing the stock up.

    This is a major new approval that expands the market for a key drug, directly lifting future revenue prospects.

  • FDA accepts filing for once-weekly oral HIV prevention pill The FDA agreed to review Gilead's once-weekly oral PrEP, with a decision expected by February 2027. If approved, it would offer a more convenient option than the current twice-yearly injection, potentially growing the HIV prevention market and lifting GILD.

    This regulatory milestone advances a new HIV prevention product, expanding Gilead's HIV franchise.

  • Positive Phase 3 data for once-weekly oral HIV treatment with Merck Gilead and Merck reported positive late-stage results for a once-weekly oral HIV treatment combining islatravir and lenacapavir. This could simplify HIV therapy and strengthen Gilead's HIV portfolio, supporting the stock.

    New clinical success in HIV treatment adds a potential future revenue stream and reinforces Gilead's leadership.

  • Full-year EPS guidance misses despite revenue beat Gilead's Q1 revenue beat expectations, but its full-year earnings-per-share guidance missed significantly. This suggests cost pressures or lower profitability ahead, which can weigh on the stock even as sales grow.

    This is a new negative financial disclosure that could cap upside from the positive pipeline news.

June 2026
▲3▼1

Gilead's Trodelvy and HIV pipeline win key approvals, but earnings guidance weighs

  • FDA and EU approve Trodelvy for first-line triple-negative breast cancer Gilead won U.S. and European approval to use Trodelvy as an initial treatment for metastatic triple-negative breast cancer, a hard-to-treat disease. This opens a much larger patient group and could significantly boost sales, pushing the stock up.

    This is a major new approval that expands the market for a key drug, directly lifting future revenue prospects.

  • FDA accepts filing for once-weekly oral HIV prevention pill The FDA agreed to review Gilead's once-weekly oral PrEP, with a decision expected by February 2027. If approved, it would offer a more convenient option than the current twice-yearly injection, potentially growing the HIV prevention market and lifting GILD.

    This regulatory milestone advances a new HIV prevention product, expanding Gilead's HIV franchise.

  • Positive Phase 3 data for once-weekly oral HIV treatment with Merck Gilead and Merck reported positive late-stage results for a once-weekly oral HIV treatment combining islatravir and lenacapavir. This could simplify HIV therapy and strengthen Gilead's HIV portfolio, supporting the stock.

    New clinical success in HIV treatment adds a potential future revenue stream and reinforces Gilead's leadership.

  • Full-year EPS guidance misses despite revenue beat Gilead's Q1 revenue beat expectations, but its full-year earnings-per-share guidance missed significantly. This suggests cost pressures or lower profitability ahead, which can weigh on the stock even as sales grow.

    This is a new negative financial disclosure that could cap upside from the positive pipeline news.

▲3▼1

Gilead's Trodelvy and HIV pipeline win key approvals, but earnings guidance weighs

  • FDA and EU approve Trodelvy for first-line triple-negative breast cancer Gilead won U.S. and European approval to use Trodelvy as an initial treatment for metastatic triple-negative breast cancer, a hard-to-treat disease. This opens a much larger patient group and could significantly boost sales, pushing the stock up.

    This is a major new approval that expands the market for a key drug, directly lifting future revenue prospects.

  • FDA accepts filing for once-weekly oral HIV prevention pill The FDA agreed to review Gilead's once-weekly oral PrEP, with a decision expected by February 2027. If approved, it would offer a more convenient option than the current twice-yearly injection, potentially growing the HIV prevention market and lifting GILD.

    This regulatory milestone advances a new HIV prevention product, expanding Gilead's HIV franchise.

  • Positive Phase 3 data for once-weekly oral HIV treatment with Merck Gilead and Merck reported positive late-stage results for a once-weekly oral HIV treatment combining islatravir and lenacapavir. This could simplify HIV therapy and strengthen Gilead's HIV portfolio, supporting the stock.

    New clinical success in HIV treatment adds a potential future revenue stream and reinforces Gilead's leadership.

  • Full-year EPS guidance misses despite revenue beat Gilead's Q1 revenue beat expectations, but its full-year earnings-per-share guidance missed significantly. This suggests cost pressures or lower profitability ahead, which can weigh on the stock even as sales grow.

    This is a new negative financial disclosure that could cap upside from the positive pipeline news.

Eli Lilly and Company (LLY)

Latest
▲3▼1

Lilly's pipeline and obesity franchise keep winning as competition and legal costs linger

  • Foundayo and Zepbound data widen Lilly's obesity lead New analyses showed higher-dose Zepbound beat high-dose Wegovy on weight loss, and oral Foundayo beat oral semaglutide on weight and blood sugar. Guggenheim raised its Foundayo sales forecasts and price target. These results support future sales and keep Lilly ahead in the obesity market.

    Obesity is Lilly's biggest profit engine, and these data points directly support its pricing power and market share.

  • FDA approvals and pipeline wins broaden Lilly beyond obesity Lilly won FDA approvals for Olumiant in kids with severe alopecia, once-weekly insulin Onswik, and Jaypirca as a first-line leukemia treatment. It also got Breakthrough status for a pancreatic cancer drug and positive eczema trial results. These add new revenue streams and reduce reliance on weight-loss drugs.

    Diversification lowers the risk of depending on one drug class and adds fresh sales growth.

  • Lilly keeps buying and partnering to fuel future growth Lilly signed a deal with InnoCare worth up to $3.35 billion, expanded its Gate Bioscience collaboration past $870 million, and opened AI drug-discovery models to biotech. The CEO said more large acquisitions are coming, funded by obesity-drug cash flow. This builds the pipeline for years ahead.

    These deals show Lilly is reinvesting its profits into new science, which supports long-term growth.

  • Competition and legal setbacks are real counterweights Novo Nordisk data showed its Ozempic had a 6% lower heart-risk than Lilly's Mounjaro, and a jury ordered Lilly to pay about $115 million to Nektar in a contract dispute. A Foghorn cancer collaboration was also halted. These are small versus Lilly's size but show it is not unbeatable.

    It gives the fair picture that Lilly faces genuine competitive and legal headwinds, not just good news.

Q3 2026
▲2▼2

Lilly hits $1T on obesity demand, but competition and coverage risks emerge

  • Lilly becomes first $1 trillion healthcare company Eli Lilly's market value crossed $1 trillion for the first time, driven by Q2 revenue jumping 47.7% to $22.97 billion and raised guidance. Mounjaro and Zepbound alone made up 65% of sales.

    This milestone and the strong financials are the core positive driver of the stock this period.

  • Pipeline advances with acquisitions and new drugs Lilly acquired AtaiBeckley for $3.8 billion, reported Alzheimer's data, won cancer approvals, and its oral GLP-1 Foundayo captured about a third of new US oral GLP-1 patients, showing broad pipeline progress.

    These pipeline and product developments support future growth and are new this period.

  • Novo Nordisk's CagriSema beats Zepbound in head-to-head trial In a direct comparison, Novo's CagriSema helped patients lose 12.4% of their weight versus 9.1% for Zepbound. This competitive threat could pressure Lilly's obesity franchise.

    This is a major new competitive risk that could hurt Lilly's market share and pricing power.

  • Coverage and pipeline setbacks raise concerns About 14% of US employers plan to drop GLP-1 coverage by 2027, and Lilly's retatrutide FDA filing slipped to early 2027. Oral Wegovy also launched in Germany, adding pressure.

    These developments threaten future demand and delay a key pipeline candidate, creating headwinds.

September 2026
▲3▼1

Lilly hits $1T on obesity drug strength, but Novo competition bites

  • Trillion-dollar milestone Eli Lilly became the first healthcare company to reach a $1 trillion market value, powered by its obesity and diabetes drugs. This milestone reflects investors' confidence in Lilly's dominant position in the fast-growing weight-loss market.

    This is the biggest new event of the period and directly explains the stock's rise.

  • Oral pill Foundayo gains traction Lilly's new oral GLP-1 pill, Foundayo, captured about a third of new US oral GLP-1 patients and launched in the UK. It also cut cardiovascular risk in a late-stage trial, expanding its potential use beyond weight loss.

    Shows a new product driving growth and broadening Lilly's market reach.

  • Pipeline and diversification progress Lilly's pipeline advanced with retatrutide showing 20.8% weight loss, plus new FDA approvals for cancer drugs Inluriyo, Verzenio, Onswik, and Jaypirca. The $6.5 billion Houston plant and AtaiBeckley acquisition further diversify beyond obesity.

    Highlights multiple new growth drivers that reduce reliance on a single drug.

  • Novo's CagriSema beats Zepbound Novo Nordisk's CagriSema delivered 12.4% weight loss in a head-to-head trial versus Zepbound's 9.1%. This competitive threat could slow Lilly's obesity market-share gains and pressure future sales growth.

    This is the main counterweight to Lilly's positive news and a real risk to its dominance.

▲5

Lilly's pipeline wins and Foundayo momentum drive growth

  • Foundayo captures one-third of new oral GLP-1 patients Lilly's oral weight-loss pill Foundayo now accounts for about one-third of new patients starting oral GLP-1 medicines, with market share rising weekly. This shows real commercial traction, supporting future sales growth and reinforcing Lilly's obesity leadership.

    This is a new update on Foundayo's market share, directly driving revenue expectations.

  • Lilly raises 2026 revenue guidance to $85-87B Lilly increased its full-year revenue outlook, reflecting strong demand for its obesity and diabetes drugs. Higher guidance signals management confidence and typically lifts investor sentiment, pushing the stock up.

    Guidance raise is a new, concrete financial update that affects valuation.

  • Retatrutide shows 20.8% weight loss in Phase 3 Lilly's experimental triple agonist retatrutide helped patients lose up to 20.8% of body weight in a Phase 3 trial, with strong blood sugar reductions. This bolsters Lilly's pipeline and future growth prospects beyond current drugs.

    New clinical data on a key pipeline asset strengthens long-term growth story.

  • Foundayo cuts cardiovascular risk in large trial In a major Phase 3 trial, Foundayo reduced the risk of heart attacks, strokes, and death compared to insulin in diabetes patients. This could expand the drug's use and strengthen its competitive position, supporting sales.

    New trial results add a cardiovascular benefit, potentially widening Foundayo's label and demand.

  • Jaypirca approved as first-line CLL/SLL treatment The FDA approved Lilly's Jaypirca for previously untreated chronic lymphocytic leukemia, based on a trial showing significantly improved progression-free survival. This expands Lilly's oncology revenue and diversifies beyond obesity.

    New regulatory approval opens a new revenue stream and reduces reliance on GLP-1 drugs.

▲3▼1

Lilly's pipeline and manufacturing expand as competition intensifies

  • FDA approves new breast cancer combo The FDA granted full approval to Lilly's Inluriyo plus Verzenio for ESR1-mutated breast cancer, based on a trial where the combo doubled progression-free survival versus Inluriyo alone. This expands Lilly's oncology offerings and adds a new revenue stream, helping diversify beyond obesity drugs.

    New approval directly boosts Lilly's oncology business and revenue potential.

  • Lilly breaks ground on $6.5B Houston plant Lilly started building a $6.5 billion manufacturing site in Houston to produce active ingredients for its medicines, including the oral obesity drug Foundayo. This is part of a $50 billion U.S. investment to expand capacity and secure supply for future growth.

    Major capital investment supports long-term production capacity and supply chain.

  • Novo's CagriSema beats Zepbound in head-to-head trial In a phase 3 trial, Novo's CagriSema helped patients lose 12.4% of their weight over 60 weeks, compared to 9.1% for Lilly's Zepbound. This suggests a competitive threat in the obesity market, potentially slowing Lilly's market share gains if CagriSema wins approval.

    Direct competitive trial result could pressure Lilly's obesity franchise.

  • FDA approves once-weekly insulin Onswik The FDA approved Lilly's Onswik, a once-weekly basal insulin for type 2 diabetes, which cuts injections from daily to weekly. This strengthens Lilly's diabetes portfolio and offers a more convenient option, potentially capturing market share from daily insulins.

    New product approval expands diabetes franchise and addresses patient convenience.

▲4

Lilly's obesity lead widens as pipeline deals and analyst targets climb

  • Foundayo grabs 30% of new US oral weight-loss patients Lilly's new obesity pill Foundayo has captured over 30% of new US patients starting oral weight-loss medicines, up from almost nothing. Novo's Wegovy pill once held about 90% of that market. This shows Lilly is winning real prescriptions, not just headlines, which supports future sales.

    Concrete evidence that Lilly's newest product is taking market share, a key growth driver.

  • Citi raises Lilly target to Street-high $1,600 Citi lifted its Lilly price target to $1,600, implying about 45% upside, even after the stock fell 8% in a month. The analyst points to Lilly's dominance in obesity prescriptions, Foundayo's prescriber growth, and retatrutide's strong trial results. This boosts investor confidence.

    A major analyst upgrade directly addresses why the stock could move higher despite recent weakness.

  • Lilly completes AtaiBeckley deal for depression drug Lilly closed its acquisition of AtaiBeckley, adding BPL-003, a rapid-acting treatment for depression that resists standard therapy. This expands Lilly's neuroscience pipeline beyond obesity, using its cash to plant seeds for future growth. It reduces reliance on weight-loss drugs.

    Shows Lilly is actively diversifying into new treatment areas, a strategic positive.

  • New data and deals bolster pipeline at EASD and beyond Lilly will present strong trial data for retatrutide, Foundayo, and eloraTZP at a major diabetes conference. It also signed new research deals with QurCan and Twist Bioscience. These moves strengthen Lilly's pipeline and technology, supporting long-term growth even if they don't boost sales immediately.

    Highlights ongoing pipeline progress and partnerships that underpin future revenue.

▲4

Lilly hits $1 trillion as obesity drugs and pipeline deals drive growth

  • Lilly hits $1 trillion market cap on obesity drug strength Lilly crossed $1 trillion in market value, with Q2 revenue up 47.7% and Mounjaro sales up 91%. The obesity franchise and expanded access are powering growth, and analysts see more upside.

    This milestone reflects the scale of Lilly's success and investor confidence, directly answering why the stock is moving.

  • J.P. Morgan raises estimates on obesity drug growth J.P. Morgan lifted 2027 revenue and EPS forecasts, keeping an Overweight rating and $1,400 target. It expects incretin sales to exceed $100 billion by 2030, driven by Zepbound, Mounjaro, and Foundayo.

    Analyst upgrades signal growing confidence in Lilly's long-term growth, a key driver of stock movement.

  • Lilly launches Foundayo in UK, first European market Lilly launched its oral weight-loss pill Foundayo in the UK, the first European market. The pill costs £100-£120 per month, much less than injections, potentially widening access and boosting sales.

    This is a concrete step in expanding Lilly's obesity franchise globally, directly supporting future revenue growth.

  • Lilly builds neuroscience as new growth driver Neuroscience revenue grew 32% to $811 million in H1 2026, led by Kisunla. Acquisitions like AtaiBeckley and Centessa add pipeline assets, diversifying beyond obesity and reducing reliance on GLP-1 drugs.

    This shows Lilly's efforts to create a second growth engine, which could sustain long-term growth and attract investors.

August 2026
▲3▼1

Lilly's Q2 Beat, Pipeline Wins Offset Rising Competition and Coverage Risks

  • Q2 earnings beat and guidance raise Lilly's Q2 revenue jumped 47.7% to $22.97 billion, beating expectations, with Mounjaro and Zepbound making up 65% of sales. Management raised guidance, signaling confidence in continued momentum.

    This is the core new financial result that drove the stock in August.

  • Pipeline and access expansion Lilly widened its lead over Novo Nordisk after CagriSema disappointed. Foundayo won UK approval, cheap access expanded via Amazon and CVS, and new deals in Alzheimer's, oncology, RNA vaccines, and immunology strengthened the pipeline.

    These new developments support future growth and competitive positioning.

  • Label expansions and cost savings Mounjaro gained a heart-risk label, broadening its use, and Zepbound showed cost savings, reinforcing its value proposition. These updates could boost demand and payer acceptance.

    New label and cost data are incremental positives for the franchise.

  • Competition and coverage headwinds Novo Nordisk launched oral Wegovy in Germany and expects a fragmented obesity market. About 14% of US employers plan to drop GLP-1 coverage by 2027, which could slow US sales growth.

    These are new competitive and reimbursement risks that could pressure future sales.

▲3▼1

Lilly's heart-label win and pipeline deals widen its lead

  • FDA expands Mounjaro label to cut heart risks The FDA approved Mounjaro to lower the risk of heart attacks, strokes and heart-related death in high-risk type 2 diabetes patients. This makes the drug useful for more people, supporting sales and pricing power, though it also increases pressure on manufacturing capacity and insurance coverage.

    A new regulatory approval directly expands the market for Lilly's biggest drug.

  • Taltz plus Zepbound shows durable one-year benefit Phase 3b trials showed combining Taltz and Zepbound helped patients with psoriatic disease and obesity achieve clearer skin and more weight loss than Taltz alone after a year. This supports using Lilly drugs together, which could boost sales across both products.

    New clinical data supports broader use of two Lilly drugs together.

  • Lilly buys Merida Biosciences for up to $2.875 billion Lilly agreed to buy Merida Biosciences for up to $2.875 billion, gaining an early-stage immunology drug for Graves' disease and thyroid eye disease. This uses cash from Lilly's obesity franchise to diversify into new treatment areas, though the drug is still years from market.

    A major acquisition shows Lilly using its cash to build new growth beyond weight-loss drugs.

  • Novo launches oral Wegovy in Germany as competition builds Novo Nordisk launched its Wegovy pill in Germany, the EU's largest drug market, and expects pills to take over a third of GLP-1 use by 2030. Lilly's Foundayo pill is in Britain and targeting 40+ markets, so this is a real race for the oral obesity market.

    A direct competitor's launch in a key market threatens Lilly's share of the growing oral GLP-1 market.

▲3▼1

Lilly's GLP-1 lead widens, but employer coverage and pricing risks build

  • Zepbound shown to cut healthcare costs in older adults A real-world study found Zepbound users over 55 had up to 38% lower healthcare costs, with savings reaching $607 per patient per month by 12 months. This evidence could persuade Medicare and insurers to cover obesity drugs, supporting demand.

    This new study directly addresses payer resistance, a key risk, by showing cost savings that could expand coverage and demand.

  • 14% of US employers to drop obesity drug coverage by 2027 A survey shows about 14% of US employers plan to end GLP-1 coverage by 2027 due to rising costs, with the share covering obesity drugs already falling from 72% to 60%. This could reduce Zepbound prescriptions and slow US sales growth.

    This is a new, concrete threat to demand from a major payer group, directly countering the positive coverage narrative.

  • FDA clears Lilly-Roche Alzheimer's blood test The FDA cleared the Elecsys pTau217 blood test, developed with Roche, as the first single-biomarker test to rule in or out Alzheimer's amyloid pathology. This could expand diagnosis and boost the market for Lilly's Alzheimer's drug donanemab.

    This new approval opens a path to wider Alzheimer's diagnosis and treatment, a potential new growth area beyond GLP-1 drugs.

  • Oncology portfolio grows 11%, diversifying beyond GLP-1 Lilly's oncology revenue rose 11% to $4.84 billion in the first half, with newer drugs like Jaypirca up 66% and Inluriyo contributing $110 million. This shows Lilly is building a second growth engine, reducing reliance on obesity drugs.

    This new data highlights a broadening revenue base, which is important for long-term growth and risk reduction.

▲3▼1

Lilly's obesity franchise keeps winning as pipeline and global reach expand

  • UK approves Foundayo for weight loss and diabetes Britain cleared Lilly's once-daily weight-loss pill Foundayo for both obesity and type 2 diabetes, the first European approval. A pill is easier for patients than injections, so it opens a new market and widens Lilly's lead over Novo's rival pill.

    New regulatory approval expands Lilly's addressable market and competitive position.

  • Lilly adds Alzheimer's and ion channel deals Lilly bought rights to an early-stage Alzheimer's drug for $10 million upfront (up to $1 billion more if it works) and teamed up with OmniAb on an ion channel program worth up to $370 million. These small bets refill the pipeline beyond weight-loss drugs.

    New deals diversify Lilly's pipeline and reduce reliance on GLP-1s.

  • Lilly partners on RNA vaccines Lilly signed a research and licensing deal with Amplitude Therapeutics to develop trans-amplifying RNA vaccines for infectious diseases, with options for two more targets. It is an early-stage move into a new treatment area, using Lilly's cash to plant seeds for future growth.

    New collaboration expands Lilly's technology base into vaccines.

  • Novo CEO says obesity market won't be winner-take-all Novo Nordisk's chief said the obesity market will split among many players, like different soda brands, rather than one winner. Novo's oral Wegovy already holds 90% of the oral GLP-1 market. This is a reminder that Lilly's dominance may face limits as competition grows.

    A real counterweight: competition could cap Lilly's long-term market share.

▲4

Lilly's obesity franchise keeps winning as new markets and legal wins add up

  • UK approves Foundayo, first market outside US Britain's regulator cleared Lilly's once-daily weight-loss pill Foundayo, the first approval outside the US. This opens a new market for a pill version of its obesity drug, which could reach patients who dislike injections. It is not yet sold through the NHS while cost regulators review it.

    A brand-new regulatory approval expands Lilly's addressable market beyond the US.

  • Amazon and CVS widen cheap access to Lilly drugs Amazon Pharmacy will offer Lilly's Zepbound pen and Foundayo pill to Medicare patients for $50 a month, and CVS expanded its weight-management program with Lilly, adding app-based access and $29 clinic visits. Easier, cheaper access should lift prescription volumes.

    New distribution deals directly increase how many patients can get Lilly's drugs.

  • Lilly sues sellers of unapproved retatrutide Lilly filed six lawsuits against businesses selling unapproved versions of retatrutide, its experimental obesity drug, and has referred over 200 parties to authorities. This protects the future franchise from unsafe copycats and keeps the market ready for the real drug when approved.

    Legal action defends a key future growth driver from illicit competition.

  • Analysts raise targets on international obesity opportunity BofA lifted its Lilly price target to $1,344 and said overseas obesity sales could eventually beat the US, with most Foundayo peak sales expected abroad. Other banks also raised targets after strong Q2 results. This reflects growing confidence in Lilly's global growth runway.

    Analyst upgrades signal that the market sees more upside from international expansion.

▲4

Lilly's Q2 Beat and Raised Guidance Cement Obesity-Drug Dominance

  • Q2 beat and raised guidance Lilly reported Q2 revenue of $22.97 billion, up 47.7%, and adjusted EPS of $8.38, beating estimates by 27%. Management raised full-year revenue guidance to $85–$87 billion and EPS to $36.25. The stock jumped as much as 7% on the news, reflecting strong demand for its obesity and diabetes drugs.

    This is the core new event that directly answers why LLY is moving right now.

  • Mounjaro and Zepbound sales surge Mounjaro sales jumped 91% to $9.94 billion and Zepbound brought in $4.93 billion, together 65% of total revenue. This shows Lilly's GLP-1 franchise is still growing rapidly, driving the earnings beat and giving confidence that demand remains strong despite competition.

    It explains the fundamental driver behind the beat-and-raise and the stock's move.

  • Novo Nordisk's setback boosts Lilly's competitive edge Novo Nordisk's next-generation obesity drug CagriSema fell short of Lilly's Zepbound in blood sugar control, and Novo guided to a sales decline and cut 9,000 jobs. This strengthens Lilly's position as the clear leader in the obesity market, which supports its pricing power and long-term growth.

    It highlights a key competitive shift that benefits Lilly and is new information.

  • Retatrutide filing planned for early 2027 Lilly plans to file for approval of its next-generation obesity drug retatrutide in early 2027. The drug helped patients lose over 20% of body weight and could also treat sleep apnea and reduce heart risk. Analysts see it as a future growth driver, though it won't contribute revenue until after 2027.

    It is a new pipeline update that reinforces Lilly's long-term growth story.

July 2026
▲2▼1

Lilly hits record on obesity demand, but competition and delays loom

  • Obesity drug demand drives record results Lilly hit record highs as demand for its obesity drugs surged, with revenue jumping 55.5% to $19.8 billion and guidance raised. JPMorgan lifted its price target to $1,400, reflecting strong confidence.

    This is the core positive driver of the stock's record performance in July.

  • Pipeline expansion and strategic investments Lilly expanded its pipeline through the $3.8 billion AtaiBeckley acquisition, positive Alzheimer's data, Canadian approval for Ebglyss, U.S. manufacturing investment, and an AI drug-discovery alliance, supporting future growth.

    These moves strengthen Lilly's long-term growth prospects and diversify its business.

  • Retatrutide shows promise but faces delays Retatrutide showed strong Phase 3 weight loss, but a heart-event imbalance bears watching. Its FDA filing slipped to early 2027 due to manufacturing data gaps, delaying a key growth driver.

    This is a key pipeline update with both positive efficacy and negative regulatory delay.

  • Competition and policy headwinds intensify Germany's rebate reform prompted Lilly to scale back manufacturing there, and Novo Nordisk won EU approval for oral Wegovy, intensifying competition. These pressures could weigh on future sales and margins.

    These are significant risks that emerged in July and could impact Lilly's growth trajectory.

▲4

Lilly's GLP-1 dominance grows as pipeline and supply expand

  • Q1 revenue surges 55.5% on Foundayo launch Lilly's first-quarter revenue jumped 55.5% to $19.8 billion, beating estimates, as new oral GLP-1 Foundayo and strong Mounjaro and Zepbound sales drove growth. Management raised full-year guidance, and an analyst set a $1,365 price target, reinforcing confidence in Lilly's earnings power.

    This shows the core financial engine behind Lilly's stock and why analysts remain bullish.

  • Retatrutide Phase 3 success, FDA filing planned Lilly's next-generation obesity drug retatrutide cut weight by up to 22.6% in Phase 3 trials, with a planned FDA submission in early 2027. This strengthens Lilly's future obesity franchise, though a slight imbalance in serious heart events bears watching.

    It confirms a major future growth driver and addresses the earlier delay, showing the pipeline is back on track.

  • Lilly expands US manufacturing with Resilience Lilly and Resilience are investing $750 million to expand U.S. production of the KwikPen injectable device, creating 400 jobs and boosting supply capacity for diabetes and obesity medicines. This helps ensure Lilly can meet soaring demand and reduces reliance on foreign manufacturing.

    It directly addresses supply constraints that could limit growth and shows Lilly investing in its core business.

  • Lilly joins Illumina's AI drug discovery alliance Lilly became a foundational participant in Illumina's Billion Cell Atlas, gaining access to massive genetic data to speed AI-driven drug discovery. This long-term move could help diversify Lilly's pipeline beyond GLP-1 drugs and keep it at the forefront of biotech innovation.

    It signals a strategic push into next-generation technology that could yield new drugs and reduce reliance on one franchise.

▲1▼1

Lilly buys depression pipeline, but retatrutide filing slips to 2027

  • Lilly to buy AtaiBeckley for up to $3.8B Lilly agreed to pay $2.8 billion upfront, plus up to $1 billion more if milestones are met, for AtaiBeckley and its experimental psychedelic depression treatment. It uses Lilly's cash to add a new growth area beyond weight-loss drugs, though the upfront cost is real.

    This is the period's biggest new deal and shows how Lilly is spending its obesity-drug profits to diversify.

  • Retatrutide approval filing delayed to early 2027 Lilly pushed back its filing for next-generation obesity drug retatrutide because it needs more manufacturing and quality-control data for regulators. The drug still worked well in trials, but the delay means a key future growth driver arrives later than expected.

    This is the main new negative and directly affects Lilly's next big obesity-drug opportunity.

▼2▲1

Lilly's obesity franchise powers growth as it expands into new drug areas

  • Germany's cost reform raises rebates, Lilly to scale back manufacturing Germany passed a law forcing drugmakers to pay higher rebates, aiming to cut €16 billion in health costs. Lilly's CEO said the company will scale back manufacturing plans there, a real headwind for its European business and investment.

    A concrete regulatory setback that could hurt Lilly's sales and expansion in a major market.

  • Lilly acquires AtaiBeckley for up to $3.8 billion Lilly is buying psychedelic drugmaker AtaiBeckley for about $2.8 billion upfront plus up to $1 billion in milestones. This adds a promising treatment for resistant depression to Lilly's pipeline, showing it is using its cash to expand beyond weight-loss drugs.

    A new strategic move that broadens Lilly's pipeline and signals long-term growth ambitions.

  • Novo Nordisk wins EU approval for oral Wegovy Novo Nordisk got EU clearance for the first oral GLP-1 pill for weight management, giving patients a pill option alongside injections. This intensifies competition for Lilly's obesity drugs in Europe, where pill preference could shift market share.

    A direct competitive threat in the key obesity market that could pressure Lilly's growth.

▲3

Lilly rides obesity-drug demand and Medicare expansion to record highs

  • JPMorgan raises price target to $1,400, stock hits record JPMorgan lifted its LLY target from $1,300 to $1,400 and reiterated overweight, citing strong demand for Mounjaro and Zepbound. The stock hit an all-time high above $1,200, with market cap surpassing $1.1 trillion. Analyst expects Q2 earnings to beat consensus.

    This is a new analyst action that directly boosted the stock and reflects confidence in future growth.

  • Lilly presents Alzheimer's data at AAIC 2026 Lilly will present 16 abstracts at the Alzheimer's conference, including new data on its Kisunla treatment and a P-tau217 blood test that could simplify diagnosis. This advances its pipeline beyond obesity, offering another long-term growth driver.

    This is a new pipeline update that shows Lilly's broader research strength beyond weight-loss drugs.

  • Canada backs Lilly's eczema drug Ebglyss Canada's drug agency gave a positive recommendation for Lilly's eczema treatment Ebglyss, which could lead to public reimbursement and wider patient access. Ebglyss is already approved in Canada and other countries, and this expands its reach.

    This is a new regulatory win that broadens Lilly's revenue base beyond obesity and diabetes.

Q2 2026
▲4

Lilly hits record on Medicare obesity coverage and cancer drug progress

  • Medicare opens obesity drugs to millions Starting July 1, Medicare's GLP-1 Bridge program offers Lilly's Zepbound and Foundayo for a flat $50 monthly copay. Up to 20 million seniors may qualify, a huge new market for obesity drugs that previously had no broad coverage.

    This is the biggest new force: a landmark policy change that expands Lilly's customer base and demand.

  • Jaypirca cancer drug advances on two fronts Europe's drug regulator recommended Jaypirca for a type of leukemia, and a Phase 3 trial showed adding it cut disease progression risk by 45%. Lilly will seek wider approvals, strengthening its cancer business beyond weight-loss drugs.

    New clinical and regulatory wins for a key cancer drug diversify Lilly's growth and support the stock.

  • Blockbuster earnings and raised guidance Lilly reported quarterly revenue of $19.8 billion, up 56% from a year ago, with Zepbound and Mounjaro contributing $12.8 billion. It raised full-year guidance to as much as $85 billion in sales and $37 in earnings per share.

    Strong financial results and higher guidance show the business is accelerating, a core reason the stock is moving.

  • Cash-rich Lilly fuels pharma deal spree A wave of drugmaker mergers in 2026, totaling $123 billion, includes Lilly using its GLP-1 cash to make bolt-on acquisitions and a $1.9 billion research deal with China's Abbisko. This helps Lilly fill its pipeline as patents expire.

    Shows how Lilly is deploying its cash to secure future growth, a strategic positive for long-term investors.

June 2026
▲4

Lilly hits record on Medicare obesity coverage and cancer drug progress

  • Medicare opens obesity drugs to millions Starting July 1, Medicare's GLP-1 Bridge program offers Lilly's Zepbound and Foundayo for a flat $50 monthly copay. Up to 20 million seniors may qualify, a huge new market for obesity drugs that previously had no broad coverage.

    This is the biggest new force: a landmark policy change that expands Lilly's customer base and demand.

  • Jaypirca cancer drug advances on two fronts Europe's drug regulator recommended Jaypirca for a type of leukemia, and a Phase 3 trial showed adding it cut disease progression risk by 45%. Lilly will seek wider approvals, strengthening its cancer business beyond weight-loss drugs.

    New clinical and regulatory wins for a key cancer drug diversify Lilly's growth and support the stock.

  • Blockbuster earnings and raised guidance Lilly reported quarterly revenue of $19.8 billion, up 56% from a year ago, with Zepbound and Mounjaro contributing $12.8 billion. It raised full-year guidance to as much as $85 billion in sales and $37 in earnings per share.

    Strong financial results and higher guidance show the business is accelerating, a core reason the stock is moving.

  • Cash-rich Lilly fuels pharma deal spree A wave of drugmaker mergers in 2026, totaling $123 billion, includes Lilly using its GLP-1 cash to make bolt-on acquisitions and a $1.9 billion research deal with China's Abbisko. This helps Lilly fill its pipeline as patents expire.

    Shows how Lilly is deploying its cash to secure future growth, a strategic positive for long-term investors.

▲4

Lilly hits record on Medicare obesity coverage and cancer drug progress

  • Medicare opens obesity drugs to millions Starting July 1, Medicare's GLP-1 Bridge program offers Lilly's Zepbound and Foundayo for a flat $50 monthly copay. Up to 20 million seniors may qualify, a huge new market for obesity drugs that previously had no broad coverage.

    This is the biggest new force: a landmark policy change that expands Lilly's customer base and demand.

  • Jaypirca cancer drug advances on two fronts Europe's drug regulator recommended Jaypirca for a type of leukemia, and a Phase 3 trial showed adding it cut disease progression risk by 45%. Lilly will seek wider approvals, strengthening its cancer business beyond weight-loss drugs.

    New clinical and regulatory wins for a key cancer drug diversify Lilly's growth and support the stock.

  • Blockbuster earnings and raised guidance Lilly reported quarterly revenue of $19.8 billion, up 56% from a year ago, with Zepbound and Mounjaro contributing $12.8 billion. It raised full-year guidance to as much as $85 billion in sales and $37 in earnings per share.

    Strong financial results and higher guidance show the business is accelerating, a core reason the stock is moving.

  • Cash-rich Lilly fuels pharma deal spree A wave of drugmaker mergers in 2026, totaling $123 billion, includes Lilly using its GLP-1 cash to make bolt-on acquisitions and a $1.9 billion research deal with China's Abbisko. This helps Lilly fill its pipeline as patents expire.

    Shows how Lilly is deploying its cash to secure future growth, a strategic positive for long-term investors.